USP28 Polyclonal Antibody, APC-Cy7 Conjugated
Applications
Reactivity
Predicted Reactivity
| Overview | |
| Catalog # | bs-5820R-APC-Cy7-100uL |
| Product Name | USP28 Polyclonal Antibody, APC-Cy7 Conjugated |
| Applications |
WB
IF(IHC-P)
IF(IHC-F)
IF(ICC)
|
| Reactivity | Mouse |
| Predicted Reactivity | Human, Rat |
| Specifications | |
| Conjugation | APC-Cy7 |
| Host | Rabbit |
| Source | KLH conjugated synthetic peptide derived from human USP28 |
| Clonality | Polyclonal |
| Isotype | IgG |
| Concentration | 1ug/ul |
| Purification | Purified by Protein A. |
| Storage Buffer | Aqueous buffered solution containing 0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| Storage Condition | Store at -20C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
| Target | |
| Gene ID | 57646 |
| Subcellular location | Nucleus |
| Synonyms | Deubiquitinating enzyme 28; KIAA1515; Ubiquitin carboxyl terminal hydrolase 28; Ubiquitin carboxyl-terminal hydrolase 28; Ubiquitin specic peptidase 28; Ubiquitin specic processing protease 28; Ubiquitin specic protease 28; Ubiquitin thioesterase 28; Ubiquitin thiolesterase 28; Ubiquitin-specic-processing protease 28; UBP28_HUMAN; USP 28; USP28; USP28 protein; USP-28. |
| Background | Deubiquitinase involved in DNA damage response checkpoint and MYC proto-oncogene stability. Involved in DNA damage induced apoptosis by specifically deubiquitinating proteins of the DNA damage pathway such as CLSPN. Also involved in G2 DNA damage checkpoint, by deubiquitinating CLSPN, and preventing its degradation by the anaphase promoting complex/cyclosome (APC/C). In contrast, it does not deubiquitinate PLK1. Specifically deubiquitinates MYC in the nucleoplasm, leading to prevent MYC degradation by the proteasome: acts by specifically interacting with isoform 1 of FBXW7 (FBW7alpha) in the nucleoplasm and counteracting ubiquitination of MYC by the SCF(FBW7) complex. In contrast, it does not interact with isoform 4 of FBXW7 (FBW7gamma) in the nucleolus, allowing MYC degradation and explaining the selective MYC degradation in the nucleolus. |
| Application Dilution | |
| WB | 1:300-5000 |
| IF(IHC-P) | 1:50-200 |
| IF(IHC-F) | 1:50-200 |
| IF(ICC) | 1:50-200 |
Frequently asked questions
Which applications is USP28 Polyclonal Antibody, APC-Cy7 Conjugated (bs-5820R-APC-Cy7) validated for, and at what dilution?
bs-5820R-APC-Cy7 is validated for WB (1:300-5000); IF(IHC-P) (1:50-200); IF(IHC-F) (1:50-200); IF(ICC) (1:50-200). These are recommended starting dilutions; optimal dilutions should be determined by the end user.
Which species does USP28 Polyclonal Antibody, APC-Cy7 Conjugated (bs-5820R-APC-Cy7) react with?
Tested reactivity: Mouse. Predicted reactivity (expected from sequence homology but not yet tested): Human, Rat.
How should bs-5820R-APC-Cy7 be stored?
Store at -20C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. Storage buffer: Aqueous buffered solution containing 0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.
What immunogen was used to raise USP28 Polyclonal Antibody, APC-Cy7 Conjugated (bs-5820R-APC-Cy7)?
KLH conjugated synthetic peptide derived from human USP28
What are the excitation and emission wavelengths of the APC-Cy7 conjugate (bs-5820R-APC-Cy7)?
APC-Cy7 on bs-5820R-APC-Cy7: excitation / emission 650nm/780nm.